1. Home
  2. STRO vs OPRX Comparison

STRO vs OPRX Comparison

Compare STRO & OPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sutro Biopharma Inc.

STRO

Sutro Biopharma Inc.

N/A

Current Price

$8.76

Market Cap

159.5M

Sector

Health Care

ML Signal

N/A

Logo OptimizeRx Corporation

OPRX

OptimizeRx Corporation

N/A

Current Price

$7.00

Market Cap

167.1M

ML Signal

N/A

Company Overview

Basic Information
Metric
STRO
OPRX
Founded
2003
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
159.5M
167.1M
IPO Year
2018
2008

Fundamental Metrics

Financial Performance
Metric
STRO
OPRX
Price
$8.76
$7.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
6
Target Price
★ $44.69
$11.90
AVG Volume (30 Days)
★ 291.0K
210.5K
Earning Date
11-12-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 124.55
EPS
N/A
★ N/A
Revenue
$38,419,000.00
★ $109,429,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8.01
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 18.78
52 Week Low
$0.72
$4.54
52 Week High
$43.85
$15.59

Technical Indicators

Market Signals
Indicator
STRO
OPRX
Relative Strength Index (RSI) 35.40 36.44
Support Level $8.11 $6.00
Resistance Level $10.77 $7.14
Average True Range (ATR) 0.85 0.76
MACD 0.14 -0.28
Stochastic Oscillator 17.01 18.97

Price Performance

Historical Comparison
STRO
OPRX

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

About OPRX OptimizeRx Corporation

OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.

Share on Social Networks: